Nicox Amends Bond Financing Agreement with Kreos and Draws Down Additional €4 Million

On October 10, 2019 Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, reported that it has amended its bond financing agreement with Kreos Capital and drawn down an additional €4 million of debt under the bond financing (Press release, NicOx, OCT 10, 2019, View Source [SID1234540955]). Nicox may now draw down a further €3 million or €8 million on December 31, 2019, subject to notice to Kreos by December 16, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of June 30, 2019, the Nicox Group had financial debt of €7.4 million under the bond financing agreement with Kreos Capital signed in January 2019. Nicox drew down €8.0 million in January 2019.